SCHEMBL21296979

SCHEMBL21296979

O=C(O)c1nn[nH]c1Oc1cccc(-c2ccc(Cl)cc2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HAO1 Q9UJM8 6/20 0.47
CTRC Q99895 1/20 0.42
XDH P47989 2/20 0.40
SLC22A12 Q96S37 2/20 0.40
CA12 O43570 1/20 0.40
ALPL P05186 1/20 0.40
NOTUM Q6P988 1/20 0.39
GRIN2D O15399 1/20 0.39
GRIN3B O60391 1/20 0.39
GRIN1 Q05586 1/20 0.39
GRIN2A Q12879 1/20 0.39
GRIN2B Q13224 1/20 0.39
GRIN2C Q14957 1/20 0.39
GRIN3A Q8TCU5 1/20 0.39
RXRA P19793 2/20 0.39
RXRB P28702 2/20 0.39
DYRK3 O43781 1/20 0.38
CDK9 P50750 1/20 0.38
DYRK1A Q13627 1/20 0.38
DYRK2 Q92630 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29799238 1.00 HAO1 (0.47) HAO1CTRCXDHSLC22A12CA12
SCHEMBL29799241 0.91 HAO1 (0.48) HAO1XDHSLC22A12RXRARXRB
SCHEMBL21296936 0.91 HAO1 (0.48) HAO1XDHSLC22A12RXRARXRB
SCHEMBL29799085 0.91 HAO1 (0.44) HAO1RXRARXRBFFAR1FFAR4
SCHEMBL21296859 0.91 HAO1 (0.44) HAO1RXRARXRBFFAR1FFAR4
SCHEMBL21296934 0.90 RXRA (0.46) HAO1XDHSLC22A12GRIN2DGRIN3B
SCHEMBL29799196 0.90 RXRA (0.46) HAO1XDHSLC22A12GRIN2DGRIN3B
SCHEMBL21296850 0.89 KMO (0.44) HAO1XDHSLC22A12DYRK3CDK9
SCHEMBL29799107 0.89 KMO (0.44) HAO1XDHSLC22A12DYRK3CDK9
SCHEMBL21312624 0.88 HAO1 (0.47) HAO1XDHSLC22A12MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11389456-B2 Compounds and methods for treating oxalate-related diseases OXALURX, INC. (US) 2022-07-19 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, LOX HAO1 14/4885CTRC 3082/4885XDH 1/4885
US-11389456-B2 Compounds and methods for treating oxalate-related diseases XDH, PNPO, LOX HAO1 14/4885CTRC 3082/4885XDH 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.